Anti-Fibrosis Compound Library

Description: Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.
MCE contains 883 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, and 2 mM for compounds with solubility between 2 mM and 10 mM.

Advantages:

• A unique collection of 883 compounds with definite or potential anti-fibrosis activity for high throughput screening (HTS) and high content screening (HCS).
• The compound library targets include TGF-β, PI3K, Wnt, MMP etc.
• A useful tool for the discovery of compounds for fibrosis diseases.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
• Structurally diverse, bioactive, and cell permeable.
• More detailed compound information with structure, IC50, and other chemical & biological data.
• High purity and quality validated by NMR and LC/MS.
• All compounds are in stock and continuously updated.

Formulation: A collection of 883 anti-gastric cancer compounds supplied as pre-dissolved Solutions or Solid.Solution:857 compounds supplied in 10 mM solution,26 compounds supplied in 2 mM solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L185-50
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L185-50
• Verpackungseinheit: 50 µl
• Mengeneinheit: STK